Lipella Pharmaceuticals (LIPO) Q3 2025 earnings summary

Executive summary

• Focused on developing reformulated generic drugs for new indications, with lead programs LP-10 (hemorrhagic cystitis) and LP-310 (oral lichen planus) in clinical development; LP-410 (oral GVHD) and LP-50 (bladder cancer) in earlier stages.

• No commercialized products; revenue derived from NIH grants, which expired in June 2025.

• Announced completion of LP-310 Phase 2a trial in Q3 2025, with positive safety and tolerability data.

• Chief Medical Officer announced retirement effective December 2025.

Financial highlights

• Revenue for Q3 2025 was $0, down from $80,380 in Q3 2024 due to grant expiration.

• Net loss for Q3 2025 was $1.25M, improved from $1.44M in Q3 2024; net loss for nine months ended September 30, 2025 was $3.89M, up from $3.57M in 2024.

• R&D expenses for Q3 2025 were $721K, down $326K year-over-year, mainly due to lower stock option expense.

• General and administrative expenses for Q3 2025 were $552K, up $60K year-over-year, driven by higher professional and outside services.

• Cash and cash equivalents at September 30, 2025 were $1.86M.

Outlook and guidance

• Existing cash expected to fund operations through the end of 2025, but additional capital will be required for continued development.

• Anticipates continued operating losses and negative cash flows due to ongoing R&D and clinical activities.